<DOC>
	<DOCNO>NCT00839241</DOCNO>
	<brief_summary>The primary objective study compare immunological status either autologous blood transfusion administer BellovacÂ® ABT allogenic blood transfusion , regard change Natural Killer ( NK ) cell frequency patient undergoing total knee replacement .</brief_summary>
	<brief_title>A Clinical Study Investigate Transfusion Patients Own Shed Blood Improves Immunological Status Comparison Transfusion Donor Blood ( `` Bank Blood '' )</brief_title>
	<detailed_description />
	<criteria>Provision inform consent Male female patient age 18 year schedule total knee replacement Subjects classify ASA Physical Status Classification System class P1 , P2 P3 accord American Society Anaesthesiology Involvement plan conduct study ( applies Astra Tech staff staff study site ) Preoperatively haemoglobin normal range judge investigator Previous enrolment randomisation treatment present study Expected confirm participation another clinical study study period Severe noncompliance protocol judge investigator and/or Astra Tech Current symptom haemophilia History presence malignant disease propensity systemic spread last 5 year Current expect use cytotoxic drug Current untreated anaemia ( e.g . sickle cell anaemia ) deem investigator Use predonation Use recombinant erythropoetin Use autologous blood transfusion Bellovac ABT , e.g . wash centrifuge blood like CellSaver</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>